Navigation Links
Combination therapy provides hope for cure of dangerous infections of cystic fibrosis patients
Date:4/24/2011

Hamilton, ON (April 24, 2011) An over-the-counter drug used to treat diarrhea combined with minocycline, an antibiotic used to treat bacterial infections, could one day change the lives of those living with cystic fibrosis.

Researchers at McMaster University have discovered this creative approach to tackle antibiotic resistance to bacterial infections, a frequent complication of those with cystic fibrosis. Cystic fibrosis is the most common, fatal genetic disease affecting Canadian children and young adults.

"Antibiotic resistance is having a profound effect on known drugs that are used to treat illness and disease," says researcher Eric Brown, professor and chair of McMaster's Department of Biochemistry and Biomedical Sciences and member of the Michael G. DeGroote Institute for Infectious Disease Research (IIDR).

"Previous advances in treating cystic fibrosis have been in managing infection, but since infectious organisms are increasingly developing resistance to antibiotics, the importance of providing new treatments is more important than ever."

Brown, who made the discovery in collaboration with McMaster researchers Gerry Wright and Brian Coombes, found that the combination of these two drugs inhibits the growth of bacteria after screening a collection of previously approved non-antibiotic drugs within McMaster's Centre for Microbial Chemical Biology.

Their screening revealed that this particular combination using the anti-diarrhea drug loperamide increases the efficacy of the antibiotic minocycline against multidrug resistant P. aeruginosa.

"Typically it takes 13 to 15 years to develop a drug," says Brown. "We think that this approach could cut drug development time in half."

"These exciting research findings hold promise that a new, safer method for treating devastating lung infections in people with cystic fibrosis may be just around the corner," says Maureen Adamson, CEO, Cystic Fibrosis Canada, a charity that partnered with the Canadian Institutes of Health Research to fund the project. "These findings could impact healthcare worldwide as antibiotic resistance is a tremendous threat to many populations."

Wright, scientific director of the IIDR, adds that McMaster is one of the only universities to look at the combination of antibiotic and non-antibiotic drugs in combating bacterial resistance. But he believes this marks the beginning of using combination therapy as a more effective way to treat disease.

"This finding has opened doors to discovering the abilities of drugs when combined," he says. "Not only has antibiotic resistance become a growing threat to managing illness and disease, the use of combination therapy has added benefits. These combinations might be a way to selectively target bacteria and combat disease and leave so-called "good bacteria" intact to do other things. In effect you use fewer antibiotics to get the same effect."


'/>"/>

Contact: Laura Thompson
lthomp@mcmaster.ca
905-525-9140, ext. 22196
McMaster University
Source:Eurekalert

Related biology news :

1. Killing drug-resistant melanoma requires combination therapy
2. Combination therapy reduced HER2-positive breast cancers
3. Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer
4. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
5. Grape news: New treatment combination safe alternative to sulfur dioxide
6. Study: Grass, fungus combination affects ecology
7. Investigators identify cleat/natural grass combination may be less likely to result in ACL injury
8. Diabetes drug kills cancer stem cells in combination treatment in mice
9. Old stain in a new combination
10. Novel therapy improves immune function in teen with rare disease
11. Umbilical cord blood-derived stem cells studied for lupus therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... ... 27, 2016 , ... The Board of Directors of Biohaven ... Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from Alexion Pharmaceuticals, Inc. ... responsible for the commercialization of multiple orphan drug indications. Mr. Tilton has ...
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, Inc., a ... Board. Dr. Lamka will assist PathSensors in expanding the use of the company‚Äôs ... the CANARY® test platform for the detection of harmful pathogens, including a number ...
(Date:4/27/2016)... ... ... Global Stem Cells Group CEO Benito Novas announced that Duncan Ross, ... Kimera Labs in Miami. , In 2004, Ross received his Ph.D. in Immunology from ... and the suppression of graft vs. host disease (GVHD) under UM Professor Robert Levy ...
(Date:4/27/2016)... MedDay, a biotechnology company focused on ... of Catherine Moukheibir as Chairman of its Board of Directors. ... Jacques Garaud , who contributed to the rapid development of ... Catherine started her career in strategy consulting and investment ... London .  She held C-Suite level roles in some ...
Breaking Biology Technology: